CRISPR Therapeutics AG (LON:0VRQ)

CRISPR Therapeutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	298.26	389.48	211.89	923.03	1,169
Short-Term Investments	1,606	1,304	1,603	1,456	521.71
Cash & Short-Term Investments	1,904	1,694	1,815	2,379	1,690
Cash Growth	12.41%	-6.70%	-23.70%	40.75%	79.10%
Accounts Receivable	25	200	-	0.31	0.14
Other Receivables	2.1	6.5	11.2	8.4	10.7
Receivables	27.1	206.5	11.2	8.71	10.84
Prepaid Expenses	6.21	7.89	26.01	29.68	15.44
Restricted Cash	-	-	0.5	-	-
Total Current Assets	1,937	1,908	1,853	2,418	1,717
Property, Plant & Equipment	277.55	305.94	320.56	312.04	93.03
Long-Term Investments	-	1.97	53.13	-	-
Other Intangible Assets	-	0.02	0.07	0.13	0.18
Other Long-Term Assets	27.35	13.57	16.28	22.2	18.14
Total Assets	2,242	2,230	2,243	2,752	1,828
Accounts Payable	14.71	38.15	27.43	14.82	9.09
Accrued Expenses	39.41	40.67	61.33	77.77	54.32
Current Portion of Leases	17.29	15.63	15.84	12.16	11.36
Current Income Taxes Payable	0.45	0.44	0.14	0.72	10.47
Current Unearned Revenue	3.85	4.11	-	1.01	2.34
Other Current Liabilities	12.08	9.81	16.38	13.4	6.67
Total Current Liabilities	87.78	108.79	121.11	119.88	94.26
Long-Term Leases	206.41	223.01	228.18	212.87	50.07
Long-Term Unearned Revenue	12.32	14.01	12.32	12.32	11.78
Other Long-Term Liabilities	3.44	0.96	5.97	7.34	7.63
Total Liabilities	309.95	346.77	367.58	352.42	163.73
Common Stock	2.7	2.5	2.44	2.39	2.28
Additional Paid-In Capital	3,294	2,878	2,735	2,598	2,236
Retained Earnings	-1,366	-999.7	-846.09	-195.92	-573.58
Treasury Stock	-0.06	-0.06	-0.06	-0.06	-0.06
Comprehensive Income & Other	1.84	1.91	-15.65	-5.07	-0.08
Total Common Equity	1,932	1,883	1,875	2,399	1,664
Shareholders' Equity	1,932	1,883	1,875	2,399	1,664
Total Liabilities & Equity	2,242	2,230	2,243	2,752	1,828
Total Debt	223.69	238.63	244.02	225.03	61.43
Net Cash (Debt)	1,680	1,457	1,624	2,154	1,629
Net Cash Growth	15.31%	-10.30%	-24.59%	32.24%	82.77%
Net Cash Per Share	19.92	18.39	20.89	26.79	24.70
Filing Date Shares Outstanding	85.77	80.28	78.65	77.07	75.43
Total Common Shares Outstanding	85.74	80.04	78.51	76.99	73.91
Working Capital	1,849	1,799	1,732	2,298	1,622
Book Value Per Share	22.53	23.52	23.89	31.17	22.52
Tangible Book Value	1,932	1,883	1,875	2,399	1,664
Tangible Book Value Per Share	22.53	23.52	23.89	31.16	22.51
Machinery	54.4	53.26	49.62	36.25	29.5
Construction In Progress	6.12	8.86	6.16	52.4	8.37
Leasehold Improvements	145.85	143.26	141.68	86.74	25.47

Source: S&P Capital IQ. Standard template. Financial Sources.